Neurocrine Biosciences is trading in a peculiar gap: short sellers are exiting at speed, yet options traders remain the most defensively positioned they have been in months — a split that tells two different stories about who still believes the post-earnings damage is done.
The short-covering trend is the week's most striking data point. Short interest collapsed 19% in a single week to 4.3% of free float — its lowest level in the 30-day window and down from a peak above 6% in early July. Over the past month, the position has shrunk by 30%. The covering looks orderly rather than panicked: cost to borrow has dropped to a negligible 0.27%, roughly half where it stood a week ago, and borrow availability is extremely loose at over 3,300% — meaning for every share currently lent out, there are 33 more available. There is no squeeze dynamic here. Shorts are leaving voluntarily.
Options tell a different story, and the contrast matters. The put/call ratio has climbed to 1.01, nearly two standard deviations above its 20-day average of 0.88 — the most defensive reading in the available history outside of the very top of the 52-week range. That is a marked change from the pattern that held through most of July, when the PCR sat comfortably below 0.87. The two signals are pointing in opposite directions: the lending market says bears are retreating, while the options market says hedgers are not done yet.
The Street's reaction to the Q2 report is broadly constructive, but the stock hasn't responded. A cluster of analysts raised targets in the days following the July 30 print — Canaccord, Truist, Wedbush, TD Cowen, Guggenheim, Cantor Fitzgerald, Piper Sandler, and RBC all lifted numbers, with targets ranging from $194 to $249. Morgan Stanley, holding an Equal-Weight, nudged its target to $196. The consensus mean sits near $213 — a 31% premium to Tuesday's close of $161.94. Bulls point to Crenessity's positive early commercial reception and a pipeline capable of extending the growth runway. Bears flag competitive pressure, regulatory execution risk, and a stock that has already priced in the optimistic scenario once before. Valuation multiples have eased — the trailing P/E has compressed nearly a full turn over 30 days to around 14x, and EV/EBITDA has slipped to roughly 12.3x — but neither looks stretched at current levels given the consensus growth case.
The earnings reaction pattern gives context to the caution. The July 30 print delivered a 7.7% single-day drop followed by a further 10.4% the next day — an 18% two-day decline that unwound months of pre-earnings positioning. The stock has partially recovered since August 6's close near $159, now trading around $162, but remains 8.6% below where it stood a month ago. The ORTEX short score has eased to 38 from 41 earlier in the week, consistent with the covering trend, though it hasn't fully reset.
With shorts covering aggressively and the borrow market completely relaxed, the remaining tension sits entirely in options hedging and the gap between the Street's targets and where the stock actually trades. The next scheduled catalyst is October 30 earnings — the question heading into that print is whether the options positioning normalises first, or whether defensive demand stays elevated as the Crenessity launch data accumulates through Q3.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
